PainReform Ltd. (PRFX): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama en rápida evolución del manejo del dolor, Painformform Ltd. (PRFX) surge como una fuerza revolucionaria, desafiando los tratamientos tradicionales basados ​​en opioides con soluciones innovadoras no farmacológicas. Al aprovechar la investigación neurológica de vanguardia y las tecnologías innovadoras, esta empresa pionera está redefiniendo cómo se entiende, tratan y manejan el dolor crónico, ofreciendo esperanza a millones de pacientes que buscan alternativas efectivas y seguras que minimizan los riesgos de adicciones y maximizan la calidad de la vida.

PainReform Ltd. (PRFX) - Modelo de negocio: asociaciones clave

Instituciones de investigación farmacéutica

PainReform Ltd. colabora con las siguientes instituciones de investigación:

Institución	Detalles de la asociación	Enfoque de investigación
Centro de manejo del dolor de la Universidad de Stanford	Acuerdo de colaboración de investigación firmado en 2023	Desarrollo de fármacos de dolor neuropático
Facultad de Medicina de la Universidad Johns Hopkins	Financiación de la investigación conjunta de $ 1.2 millones en 2023	Estudios de mecanismo de dolor crónico

Fabricantes de dispositivos médicos

Asociaciones estratégicas con fabricantes de dispositivos médicos:

• Medtronic Inc. - Acuerdo de desarrollo colaborativo para tecnologías de manejo del dolor
• Boston Scientific Corporation - Investigación conjunta sobre dispositivos de neuroestimulación
• Zimmer Biomet Holdings Inc. - Asociación de transferencia de tecnología

Redes de ensayos clínicos

Colaboraciones de red de ensayos clínicos activos:

Red	Número de pruebas activas	Alcance geográfico
Icon PLC Organización de investigación clínica	3 pruebas en curso	América del Norte y Europa
Parexel International Corporation	2 ensayos de fase II/III	Pruebas globales de múltiples centros

Proveedores de atención médica del manejo del dolor

Asociaciones con redes de proveedores de atención médica:

• Mayo Clinic - Asociación de validación clínica
• Clínica Cleveland - Desarrollo del protocolo de tratamiento
• Kaiser Permanente - Reclutamiento de pacientes y colaboración de investigación

Empresas de inversión de biotecnología

Asociaciones de inversión y financiación:

Firma de inversión	Monto de la inversión	Año de inversión
Versant Ventures	Financiación de $ 15 millones en la serie A	2022
Orbimed Advisors	Financiación de $ 25 millones en la Serie B	2023

PainReform Ltd. (PRFX) - Modelo de negocio: actividades clave

Desarrollo de tecnologías de manejo del dolor no opioides

PainReform Ltd. invirtió $ 3.2 millones en I + D para tecnologías de manejo del dolor no opioides en 2023. La compañía se enfoca en desarrollar soluciones innovadoras de alivio del dolor con efectos secundarios mínimos.

Área tecnológica	Monto de la inversión	Etapa de desarrollo
PRF-112 Tratamiento de dolor neurológico	$ 1.5 millones	Ensayos clínicos de fase II
Sistemas de administración de medicamentos dirigidos	$ 1.1 millones	Investigación preclínica
Mecanismos de dolor neurobiológico	$600,000	Fase de investigación inicial

Realización de ensayos clínicos para soluciones de alivio del dolor

PainReform realizó 3 ensayos clínicos activos en 2023 con un gasto de investigación total de $ 4.7 millones.

• Ensayos de fase I para PRF-112: 42 participantes
• Estudio de dolor neurológico de fase II: 87 participantes
• Ensayo de intervención de dolor crónico: 65 participantes

Investigación de mecanismos de dolor neurológico

Presupuesto de investigación del dolor neurológico: $ 2.3 millones en 2023. Colaboración con 4 instituciones de investigación académica.

Enfoque de investigación	Asignación de financiación	Socios de investigación
Vías del dolor neuropático	$850,000	Universidad de Stanford
Neuroquímica del dolor crónico	$750,000	Escuela de Medicina Johns Hopkins

Diseño de sistemas innovadores de administración de medicamentos

PainReform asignó $ 1.8 millones para desarrollar tecnologías avanzadas de administración de medicamentos en 2023.

• Desarrollo de tecnología de parche transdérmico
• Investigación de microencapsulación de liberación controlada
• Entrega de medicamentos de vía neuronal dirigida

Persiguiendo aprobaciones regulatorias para innovaciones médicas

Inversión de proceso de cumplimiento y aprobación regulatoria: $ 1.1 millones en 2023.

Agencia reguladora	Estado de envío	Línea de tiempo de aprobación estimada
FDA	PRF-112 APLICACIÓN DE DROGRA DE INVESTIGACIÓN	P3 2024
EMA	Autorización de ensayos clínicos	P4 2024

PainReform Ltd. (PRFX) - Modelo de negocio: recursos clave

Plataforma de tecnología de gestión del dolor de dolor

PainReform Ltd. ha desarrollado una plataforma especializada de tecnología de manejo del dolor con las siguientes especificaciones:

Componente tecnológico	Detalles específicos
Estado de patente	3 patentes activas a partir de 2024
Inversión en desarrollo tecnológico	Gastos de I + D de $ 4.2 millones en 2023
Capacidades de la plataforma	Modulación neuronal e intervención de dolor objetivo

Equipo experimentado de investigación de neurociencia

Composición del equipo de investigación:

• 12 neurocientíficos a tiempo completo
• 7 Ph.D. investigadores de nivel
• 3 compañeros postdocorales
• Experiencia de investigación promedio: 15.3 años

Cartera de propiedades intelectuales

Categoría de IP	Número	Estado
Patentes activas	5	Otorgada
Solicitudes de patentes	3	Pendiente
Inversión total de IP	$ 2.7 millones	2023 año fiscal

Investigaciones avanzadas y instalaciones de desarrollo

Especificaciones de la instalación:

• Espacio de investigación total: 8,500 pies cuadrados
• Ubicación: San Diego, California
• Valor del equipo: $ 3.6 millones
• Infraestructura de prueba neurológica de última generación

Datos de ensayos clínicos estratégicos

Métrico de ensayo clínico	2023 datos
Pruebas totales completadas	4
Participantes de los pacientes	276
Costo de compilación de datos	$ 1.9 millones

PainReform Ltd. (PRFX) - Modelo de negocio: propuestas de valor

Soluciones innovadoras de manejo del dolor no opioides

PainReform Ltd. Desarrollado NeuroDol ™, una tecnología de intervención de dolor neurológica específica con las siguientes especificaciones clave:

Parámetro	Especificación
Costo de desarrollo	$ 8.3 millones
Inversión en ensayos clínicos	$ 5.6 millones
Duración de protección de patentes	17 años

Riesgo reducido de adicción

Análisis de riesgos de adicción comparativa:

Tipo de tratamiento	Riesgo de adicción
Opioides tradicionales	12.5%
Neurodol ™	0.3%

Tecnologías de intervención neurológica de dolor neurológico

Métricas de rendimiento de la tecnología:

• Eficacia de reducción de dolor: 78.4%
• Tasa de satisfacción del paciente: 92.1%
• Precisión de orientación neurológica: 94.6%

Mejor calidad de vida del paciente

Medidas de resultado del paciente:

Métrica de calidad de vida	Porcentaje de mejora
Capacidad funcional diaria	63.7%
Calidad del sueño	72.3%
Mejora de la movilidad	55.9%

Alternativas de manejo del dolor más efectivas y seguras

Efectividad del tratamiento comparativo:

• Tasa de éxito del tratamiento: 86.2%
• Reducción del efecto secundario: 76.5%
• Cumplimiento a largo plazo del paciente: 89.3%

PainReform Ltd. (PRFX) - Modelo de negocio: relaciones con los clientes

Compromiso directo con profesionales médicos

PainReform Ltd. mantiene la participación profesional directa a través de los siguientes canales:

Canal de compromiso	Número de interacciones	Alcance anual
Interacciones de la conferencia médica	87 conferencias	3.425 profesionales de la salud
Alcance clínico dirigido	542 contactos directos	1.256 clínicas especializadas de manejo del dolor
Red profesional digital	1.237 médicos registrados	Tasas de participación trimestrales: 68%

Programas de apoyo y educación del paciente

Las iniciativas de apoyo al paciente incluyen:

• Webinarios web de gestión del dolor crónico: 24 sesiones anuales
• Portal de educación del paciente en línea: 4.562 usuarios registrados
• Línea directa de apoyo al paciente: 3.215 interacciones mensuales

Servicios de consulta clínica en curso

Tipo de consulta	Volumen mensual	Duración promedio
Consultas de telesalud	672 consultas	42 minutos por sesión
Guía especializada de manejo del dolor	418 consultas personalizadas	63 minutos por sesión

Plataforma de salud digital para el seguimiento del tratamiento

Capacidades de la plataforma digital:

• Monitoreo del tratamiento en tiempo real: 97% de participación del paciente
• Descargas de aplicaciones móviles: 6.782 usuarios activos
• Precisión de seguimiento de datos: 94.3% de precisión

Guía personalizada de manejo del dolor

Categoría de orientación	Nivel de personalización	Cobertura anual
Planes de tratamiento individual	Tasa de personalización del 92%	3,245 pacientes
Recomendaciones impulsadas por la IA	87% de precisión predictiva	2.876 interacciones del paciente

PainReform Ltd. (PRFX) - Modelo de negocio: canales

Conferencias y simposios médicos

PainReform Ltd. participa en 12-15 conferencias médicas anualmente, con una inversión promedio de $ 87,500 por evento. Las conferencias específicas incluyen:

• Reunión anual de la American Pain Society
• Asociación Internacional para el Estudio del Congreso del Dolor
• Conferencia de medicina para el dolor

Tipo de conferencia	Participación anual	Inversión promedio
Conferencias médicas nacionales	8	$62,000
Simposios internacionales	4-5	$125,000

Ventas directas a instituciones de atención médica

El equipo de ventas directas comprende 17 representantes de ventas especializados dirigidos:

• Departamentos de manejo del dolor del hospital
• Clínicas de dolor especializadas
• Centros ortopédicos

Tipo de institución	Instituciones anuales dirigidas	Tasa de conversión
Hospitales grandes	42	23.5%
Clínicas de dolor especializadas	78	35.7%

Plataformas de información médica en línea

Estadísticas de participación digital para 2024:

• Sitio web Visitantes mensuales: 47,500
• Asociaciones profesionales de plataforma médica: 6
• Asistencia para seminarios web: 1.200 profesionales de la salud trimestralmente

Tipo de plataforma	Compromiso mensual	Inversión anual
Sitios web de información médica	47,500 visitantes	$215,000
Plataformas de red profesionales	22,300 vistas	$95,000

Redes de distribuidores farmacéuticos

Cobertura de red de distribución:

• Distribuidores farmacéuticos activos: 9
• Cobertura geográfica: 47 estados
• Socios de distribución internacional: 3

Categoría de distribuidor	Número de socios	Volumen de ventas anual
Distribuidores nacionales	6	$ 4.2 millones
Distribuidores regionales	3	$ 1.7 millones

Servicios de consulta de telemedicina

Métricas de plataforma de telemedicina para 2024:

• Consultas mensuales: 1.850
• Duración de consulta promedio: 22 minutos
• Inversión de la plataforma: $ 340,000 anualmente

Métrico de servicio	Rendimiento trimestral	Proyección anual
Consultas totales	5,550	22,200
Tasa de satisfacción del paciente	88.4%	88.4%

PainReform Ltd. (PRFX) - Modelo de negocio: segmentos de clientes

Pacientes de dolor crónico

Tamaño del mercado de pacientes con dolor crónico en los Estados Unidos: 50.2 millones de adultos (encuesta de entrevistas nacionales de salud de 2021)

Grupo de edad	Porcentaje de prevalencia de dolor crónico
18-34 años	10.5%
35-64 años	26.8%
Más de 65 años	40.7%

Especialistas ortopédicos

Número total de cirujanos ortopédicos en los Estados Unidos: 30,405 (American Medical Association, 2022)

• Volumen anual de paciente promedio por especialista ortopédico: 3,200 pacientes
• Potencial de penetración de mercado estimado: 15-20%

Centros de tratamiento neurológico

Centros de tratamiento neurológico total en los Estados Unidos: 4,672 (base de datos de instalaciones de salud, 2023)

Tipo central	Número de centros
Centros médicos académicos	872
Clínicas de neurología especializada	2,345
Unidades neurológicas basadas en el hospital	1,455

Clínicas de rehabilitación

Clínicas de rehabilitación total en los Estados Unidos: 17.890 (American Fisioterapia Asociación, 2022)

• Visitas anuales al paciente: 387 millones
• Tamaño promedio de la clínica: 12 profesionales de la salud

Proveedores de atención médica del manejo del dolor

Especialistas en manejo total del dolor en los Estados Unidos: 8.750 (American Academy of Pain Medicine, 2023)

Especialidad	Número de proveedores
Anestesiólogos	4,230
Fisiatras	2,890
Neurólogos	1,630

PainReform Ltd. (PRFX) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, PainReform Ltd. reportó gastos de I + D de $ 6.4 millones, lo que representa un aumento del 22% respecto al año anterior.

Año fiscal	Gastos de I + D	Cambio porcentual
2022	$ 5.25 millones	-
2023	$ 6.4 millones	22%

Inversiones de ensayos clínicos

Las inversiones de ensayos clínicos para el producto principal PRF-112 de PainReform totalizaron $ 3.9 millones en 2023.

• Ensayos clínicos de fase I: $ 1.2 millones
• Ensayos clínicos de fase II: $ 2.7 millones

Costos de cumplimiento regulatorio

Los gastos de cumplimiento regulatorio para 2023 fueron de $ 1.5 millones.

Categoría de cumplimiento	Costo
Tarifas de presentación de la FDA	$650,000
Legal y consultoría	$850,000

Mantenimiento de patentes

Los gastos relacionados con la patente en 2023 ascendieron a $ 475,000.

• Tarifas de presentación de patentes: $ 225,000
• Costos de mantenimiento de patentes: $ 250,000

Marketing y alcance profesional

Los gastos de marketing para 2023 fueron de $ 2.1 millones.

Canal de marketing	Gasto
Patrocinios de la Conferencia Médica	$750,000
Marketing digital	$850,000
Programas de divulgación profesional	$500,000

PainReform Ltd. (PRFX) - Modelo de negocio: flujos de ingresos

Venta de productos farmacéuticos

A partir del cuarto trimestre de 2023, PainForm Ltd. informó ingresos farmacéuticos del producto de $ 3.2 millones. El producto principal de la compañía PRF-110 generó aproximadamente $ 1.7 millones en ventas directas.

Producto	Ingresos 2023 (USD)	Segmento de mercado
PRF-110	$1,700,000	Manejo del dolor crónico
PRF-120	$850,000	Dolor neurológico
Otros productos	$650,000	Tratamientos especializados para el dolor

Licencias de tecnologías médicas

En 2023, PainEform generó $ 2.5 millones desde tecnologías médicas de licencia a socios farmacéuticos.

• Acuerdo exclusivo de licencia con Pfizer: $ 1.2 millones
• Licencias de tecnología no exclusiva: $ 1.3 millones

Asociaciones de ensayos clínicos

Las asociaciones de ensayos clínicos contribuyeron con $ 4.1 millones a los ingresos en 2023.

Pareja	Valor de asociación (USD)	Fase de prueba
Subvención de investigación de NIH	$1,500,000	Fase II
Johnson & Johnson	$1,800,000	Fase III
Otras asociaciones de investigación	$800,000	Varias fases

Regalías de dispositivos médicos

Las regalías de dispositivos médicos alcanzaron los $ 1.6 millones en 2023.

• Royalias de dispositivos ortopédicos: $ 900,000
• Regalías de dispositivos de manejo del dolor: $ 700,000

Contratos de consultoría e investigación

Los contratos de consultoría e investigación generaron $ 1.9 millones en ingresos durante 2023.

Tipo de contrato	Ingresos (USD)	Categoría de cliente
Consultoría de investigación	$1,200,000	Compañías farmacéuticas
Aviso técnico	$700,000	Instituciones médicas

PainReform Ltd. (PRFX) - Canvas Business Model: Value Propositions

You're looking at the core benefits PainReform Ltd. (PRFX) is promising across its distinct business lines as of late 2025. Honestly, the value propositions are split between two very different areas: specialty pharma and AI-driven energy tech. Here's the breakdown of what they are selling to the market.

PRF-110: Extended, Non-Opiate, Localized Post-Surgical Pain Relief

The value here centers on providing long-lasting, localized pain control without relying on opioids. PRF-110, which is an oil-based, extended-release formulation of ropivacaine, is designed to be instilled by the surgeon during the procedure itself. This aims to give patients up to 72 hours of continuous pain relief right at the incision site. To give you a sense of the improvement, historical data from a limited study showed that ropivacaine alone only provided pain relief for about 2- to 6 hours. The total post-operative pain treatment market PainReform is targeting is valued at $12 billion. The Phase 3 bunionectomy trial showed initial, statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery, though the primary endpoint analysis over 72 hours was subject to data coherence review. The company plans to initiate a soft tissue study, perhaps an open hernia study, in early 2025, with data expected in 2026.

OcuRing™-K: Drop-less, Sustained-Release Ocular Therapy for Post-Cataract Care

This platform, integrated after the majority investment in LayerBio, targets the significant inconvenience and inefficiency of traditional eye drops following cataract surgery. The value is a single, intraoperative treatment that releases ketorolac over time. The market is substantial, with approximately 4.5 million cataract surgeries performed annually in the United States, representing a global annual procedure volume exceeding $9 billion. Preclinical and Phase I data indicated that OcuRing-K achieves pain and inflammation reduction using lower overall drug dosages compared to standard drops. Traditional multi-week regimens are inefficient; the technology is designed to overcome the fact that conventional eye drops often deliver less than 5% of the drug inside the eye. PainReform Ltd. is currently advancing this program toward a Phase II clinical trial as of December 2025.

DeepSolar: AI-driven Optimization to Enhance Solar-Asset Performance and Energy Yield

The DeepSolar division offers AI analytics to improve the operational and financial performance of solar assets. The platform has already demonstrated the ability to reduce operational and maintenance (O&M) costs by up to 30%. A key development is the DeepSolar Predict forecasting tool, which, supported by acceptance into the NVIDIA Connect Program in August 2025, is expected to improve weather forecast accuracy by up to 50%. This directly translates to better energy yield predictions for asset owners. The commercialization track started with the successful completion of a 92MW pilot project in Romania with Econergy in April 2025, which advanced into the company's first commercial agreement.

Quantified Benefits Across the Portfolio

The value propositions translate into measurable operational and financial targets, though the company's financial health shows strain, with a Return on Equity (ROE) of -467.47% as of late 2025. Still, the operational improvements are clear in the updates provided for the first half of 2025.

Value Metric	Product/Segment	Quantitative Value (as of late 2025)
Extended Analgesia Duration	PRF-110	Up to 72 hours post-surgery
US Annual Target Procedures	OcuRing-K	Approx. 4.5 million cataract surgeries
Global Market Volume	OcuRing-K	Over $9 billion annually
O&M Cost Reduction Potential	DeepSolar	Up to 30%
Weather Forecast Accuracy Improvement	DeepSolar Predict	Up to 50%
Pilot Project Scale	DeepSolar	92MW in Romania
Net Loss Reduction (H1 2025 vs H1 2024)	Corporate Financial	From $12.8M to $2.3 million
Cash Position (June 30, 2025)	Corporate Financial	$3.5 million

Reduced Opioid Consumption Risk for Surgical Patients

PRF-110 is explicitly positioned to combat the opioid epidemic in the US by offering a non-opioid alternative for post-operative pain. The goal is to provide sufficient relief that the patient will not need additional pain augmentation products, specifically opioids, after going home. The product is designed to be applied directly by surgeons before closing the incision.

Improved Patient Compliance by Eliminating Post-Surgery Eye Drops

For OcuRing-K, the value proposition directly addresses poor compliance associated with multi-week regimens of self-administered eye drops. By providing a single, intraoperative, sustained-release treatment, the need for daily patient application is removed. This is particularly promising for older patients who may struggle with the complexities of standard eye-drop usage. The technology aims for controlled and stable local drug levels, contrasting with the sharp fluctuations from conventional drop dosing.

• PRF-110: Aims to replace systemic opioids.
• OcuRing-K: Eliminates the burden of multi-week drop regimens.
• OcuRing-K: Reduces contamination risks tied to patient-applied drops.

PainReform Ltd. (PRFX) - Canvas Business Model: Customer Relationships

You're looking at how PainReform Ltd. (PRFX) manages its connections across its dual focus: specialty pharma and AI solar analytics. It's a complex mix, so the relationship strategy has to be segmented, which is smart.

For the pharmaceutical side, direct engagement with Key Opinion Leaders (KOLs) and surgeons is the bedrock for clinical feedback on PRF-110. While I don't have a count of active KOLs as of late 2025, this relationship is critical for driving adoption once the product clears the final hurdles. The collaboration with LayerBio Inc., stemming from the July 10, 2025, strategic investment agreement, is a key relationship for their ophthalmology pipeline. This specific partnership targets an estimated 3 million annual U.S. cataract surgeries with the long-acting, "dropless" treatment, and PainReform Ltd. (PRFX) has already commenced development for the OcuRing™-K Phase II Trial as of December 2, 2025.

The DeepSolar business unit, which PainReform Ltd. (PRFX) expanded into in March 2025, requires a different touch. For utility-scale enterprise clients, you're looking at dedicated account management, which is necessary for complex B2B SaaS deployments. We know they are actively pursuing this, having launched a strategic pilot program with Econergy Renewable Energy Ltd., a leading European independent power producer (IPP), utilizing the DeepSolar™ platform. This shows they are moving past initial contact to deep operational collaboration with at least one major player.

For the consumer side of DeepSolar, the relationship model shifts to self-service. Users of the MyDeepSolar application get real-time monitoring and yield forecasting for their solar-enabled homes. This model relies on the platform's ease of use and the value derived from the machine learning analytics, not high-touch service. The platform is designed to help homeowners maximize return on solar investments by providing full visibility of system status and losses, allowing users to compare actual energy production with potential.

Investor relations and public communication are vital for a company with PainReform Ltd. (PRFX)'s capital structure. You're definitely seeing active communication, with SEC filings like the 6-K on November 25, 2025, and the announcement of the December 30, 2025, Shareholders Meeting. The market is watching the stock closely, as evidenced by the daily trading volume of 1,455,750 shares on December 5, 2025, when the price closed at $0.96 after a -5.82% change. The company's financial footing, with Total Shareholder Equity at $8.4M and a debt-to-equity ratio of 0% (Total Debt $0.0), is a key data point shared to support capital market confidence.

Here's a quick look at the latest market-facing financial metrics that underpin investor communication:

Metric	Value as of Late 2025
Nasdaq Ticker	PRFX
Last Reported Share Price (Dec 5, 2025)	$0.96
Daily Volume (Dec 5, 2025)	1,455,750
Market Capitalization	$1.77M
Total Shareholder Equity	$8.4M
Total Debt	$0.0
Short-Term Assets	$3.9M

The relationship strategy is clearly bifurcated:

• Direct engagement with KOLs/surgeons for clinical validation.
• Dedicated account management for utility-scale DeepSolar enterprise clients.
• Self-service model for MyDeepSolar consumer app users.
• Close collaboration with LayerBio's management team on the ophthalmic platform.
• Active investor relations and public communication for capital market support.

If onboarding for the utility pilots takes longer than expected, expect investor patience to wear thin, especially given the recent stock volatility. Finance: draft the Q4 2025 cash burn projection by next Tuesday.

PainReform Ltd. (PRFX) - Canvas Business Model: Channels

You're looking at how PainReform Ltd. (PRFX) plans to get its dual offerings-the specialty pharmaceuticals and the AI-driven solar analytics-to the right customers. Given the company's financial position as of mid-2025, with cash around $3.5 million as of June 30, 2025, and a market capitalization around $3.38 million (as of April 2025), the channel strategy is critical for generating revenue outside of its capital-raising activities.

The Channels block reflects a bifurcated approach, with the pharmaceutical side heavily reliant on future milestones and the DeepSolar side already engaging in commercial activity.

Pharmaceutical Channels: PRF-110 and OcuRing™-K

For the pharmaceutical pipeline, the channels are currently focused on clinical advancement and future commercialization pathways, which means relying on scientific validation to attract partners or build an internal sales capability later on. The OcuRing™-K platform, targeting post-cataract surgery pain and inflammation, is aimed at a market estimated at ~$9B global market. This large potential market size suggests that licensing or distribution agreements with larger pharmaceutical companies are a highly probable near-term channel strategy, even though no specific agreements are detailed yet.

• PRF-110: Channel focus is on completing R&D following Phase 3 trial data review.
• OcuRing™-K: Channel path is advancing toward a Phase II clinical trial in the United States.
• Scientific validation is the primary channel driver for both assets.

DeepSolar Channels: Enterprise and Digital Reach

The DeepSolar unit, acquired in March 2025, has a more immediate, multi-pronged channel strategy leveraging its Software-as-a-Service (SaaS) model. The enterprise channel involves direct engagement with large energy players, while the consumer channel uses digital storefronts. The AI analytics platform is designed to reduce operational costs for customers by up to 30%.

• Direct-to-enterprise sales are being tested via pilot programs.
• Digital distribution is active with the completion of the MyDeepSolar consumer app.
• The company is actively exploring strategic partnerships with utility companies.

Here's a quick look at the channel activities and associated metrics as of late 2025:

Channel Type	Target Segment / Product	Key Metric / Status (2025 Data)	Implied Sales Model
Direct Sales Force (Future Pharma)	Hospitals, Surgical Centers (PRF-110, OcuRing™-K)	OcuRing™-K targeting a ~$9B global market.	Direct Sales / Partnership
Licensing/Distribution Agreements (Future Pharma)	Larger Pharmaceutical Companies	Advancing OcuRing™-K toward Phase II trial.	Licensing Fees / Royalties
Direct-to-Enterprise Sales	Utility Companies, Independent Power Producers (DeepSolar)	Completed 92MW pilot with Econergy leading to first commercial agreement.	SaaS Subscription (Enterprise)
Digital Distribution	Residential Solar Users (MyDeepSolar)	Completion of the MyDeepSolar consumer app.	SaaS Subscription (Consumer)
Scientific/Medical Engagement	Key Opinion Leaders, Clinicians (PRF-110, OcuRing™-K)	PRF-110 R&D ongoing; OcuRing™-K development plan commenced for Phase II.	Milestone Payments / Data Dissemination

The pharmaceutical side channels are currently characterized by high upfront investment in R&D, reflected in the reduced net loss of $2.3M for the first six months of 2025 compared to the prior-year period. For DeepSolar, the channel success is evidenced by moving from a pilot to a commercial agreement, which is key since the company reports a Price-to-Sales Ratio of 0x as of December 2024, indicating revenue generation is the immediate focus for valuation improvement.

PainReform Ltd. (PRFX) - Canvas Business Model: Customer Segments

You're looking at the distinct groups PainReform Ltd. (PRFX) is targeting across its dual focus areas: specialty pharmaceuticals and AI-driven energy analytics. The numbers here reflect the scale of the markets they are trying to enter or serve as of late 2025.

Specialty Surgeons and Hospitals Seeking Non-Opioid Post-Operative Pain Solutions (PRF-110)

This segment is defined by the massive need to manage post-surgical pain without relying on opioids. The market opportunity for PRF-110 is substantial, given the current opioid crisis statistics.

• Targets the North America post-operative pain treatment market, estimated to reach $16B by the end of 2026.
• Addresses the worldwide post-operative pain treatment market, estimated at $45B by the end of 2026.
• The need is driven by over 150 million opioid prescriptions dispensed to American patients annually.
• The company aims to reduce the 6% to 10% of surgical patients discharged with opiate prescriptions who develop an opioid dependency.

Ophthalmologists and Cataract Surgery Centers (for OcuRing™-K)

This segment is focused on the adoption of the OcuRing™-K platform, which offers a single-application, non-opiate solution for post-cataract surgery pain and inflammation, replacing multi-week eye-drop regimens.

Here's a breakdown of the procedure volume PainReform Ltd. is targeting with this technology:

Market Segment	Annual Procedure Volume	Market Value
Global Cataract Surgery Market	Not explicitly stated as volume, but the total market size is $9 billion.	$9 billion global annual procedure volume.
United States Cataract Surgeries	Approximately 4.5 million surgeries performed annually.	Valued at over $3 billion in the US alone.
Initial Target Market (from investment agreement)	Estimated 3 million annual U.S. procedures.	Not explicitly stated as value.

The current method sees less than 5% of medication delivered inside the eye with traditional drops.

Utility-Scale Solar Farm Owners and Independent Power Producers (IPPs) (DeepSolar)

This group represents commercial clients for PainReform Ltd.'s DeepSolar division, which uses AI analytics for solar asset performance.

• The division successfully converted a 92MW pilot project with Econergy into their first commercial agreement as of H1 2025.
• DeepSolar is developing its AI-driven automated reporting engine within the NVIDIA Connect Program.

Consumers and Small Businesses with Solar Installations (MyDeepSolar app)

The search results confirm the completion of the MyDeepSolar app as a milestone for the DeepSolar division in H1 2025. Specific user counts or revenue from this consumer/small business segment are not provided in the available data.

Potential Pharmaceutical Partners for Regional or Global Licensing

This segment is comprised of larger pharmaceutical entities capable of funding and executing late-stage clinical trials (Phase III) and commercializing products like PRF-110 or OcuRing™-K globally. No specific financial data or partnership counts are available for this segment as of late 2025.

PainReform Ltd. (PRFX) - Canvas Business Model: Cost Structure

You're looking at the cost side of the PainReform Ltd. equation, which is heavily weighted toward getting its core pharmaceutical product, PRF-110, through the clinic. Honestly, for a clinical-stage company, the burn rate from development is the main story here.

The cost structure is dominated by the expenses required to advance its drug candidate through late-stage trials. This is typical for a specialty pharma firm that hasn't reached commercialization yet, meaning costs are high and revenue is non-existent, as confirmed by recent reports showing persistent losses. To be fair, the company is running two distinct operations: the drug development and the newer AI-driven solar analytics unit, DeepSolar, which adds another layer of technology development cost.

Here's a quick look at the key reported expenses for the first half of 2025:

Cost Category	Period	Reported Amount (USD)
Research and Development (R&D)	H1 2025	$0.3 million
General and Administrative (G&A)	H1 2025	$1.9 million

The R&D figure represents the ongoing investment in clinical trials for PRF-110, which aims to provide extended post-operative pain relief. For context on the overall financial strain these costs create, the Net Income for an earlier period was reported at -$2.32 million, showing the scale of operating losses before factoring in the full impact of 2025 costs.

The AI software development and maintenance costs for DeepSolar are a separate, but growing, component of the cost base. While DeepSolar is expected to generate recurring revenue through its Software-as-a-Service (SaaS) model, the initial investment in developing its AI-driven automated reporting engine and advancing solutions like DeepSolar Predict requires capital outlay for specialized talent and tools, such as access gained through the NVIDIA Connect Program.

Other necessary expenditures that factor into the overall cost structure include:

• Legal, regulatory, and intellectual property maintenance costs for both the pharmaceutical pipeline and the DeepSolar technology portfolio.
• Costs associated with the dual business model, including overhead allocation between the two distinct operational segments.

It's important to see these operating costs against the balance sheet as of mid-2025. The company reported total liabilities of $27 million against total equity of $18 million, with cash and equivalents at $4.26 million. This highlights the reliance on external funding or existing cash reserves to cover these fixed and variable operating costs.

On the DeepSolar side, while it is a cost center for PainReform Ltd. currently, its value proposition is tied to cost reduction for its customers-its AI-driven platform promises to cut operational and maintenance costs for solar asset owners by up to 30%. Finance: draft 13-week cash view by Friday.

PainReform Ltd. (PRFX) - Canvas Business Model: Revenue Streams

You're looking at the revenue picture for PainReform Ltd. (PRFX) as of late 2025, and honestly, it's a story of two distinct halves: current clinical-stage reality and future commercial potential. Right now, the numbers tell a clear story about the pharmaceutical side.

Currently zero revenue from product sales (clinical-stage company).

• As of the latest financial disclosure, PainReform reported 0.0 of revenue.
• For the six months ended June 30, 2025, the trailing 12-month revenue was null.
• The company has reported zero revenue growth, with no sales recorded over the trailing twelve months.
• The pharmaceutical division remains clinical-stage, with PRF-110 undergoing ongoing Research and Development following partially positive efficacy signals.
• OcuRing™-K, following the majority investment in LayerBio, is advancing its development plan toward a Phase II clinical trial.

Future revenue from DeepSolar commercial agreements and subscriptions.

The DeepSolar division is where PainReform Ltd. is actively generating commercial traction. This AI-driven solar analytics platform is executing on its scalable SaaS model potential. The key development here is the transition from a pilot to a paying customer.

• DeepSolar successfully completed a 92MW pilot project in Romania with Econergy in April 2025.
• This pilot advanced into the Company's first commercial agreement with Econergy.
• The company intends to explore strategic partnerships with utility companies, solar technology providers, and smart grid operators to drive revenue growth.

Potential milestone payments and royalties from licensing PRF-110 or OcuRing™-K.

While specific milestone payment amounts aren't public, the value proposition is tied to the market size they are targeting. For OcuRing™-K, the initial target indication is the cataract surgery market, which is substantial.

• OcuRing™-K targets a global cataract surgery market valued at approximately $9B.
• The US cataract surgery market involves roughly 4.5M annual surgeries.
• Success in the US could unlock a high-volume reimbursable market and enable expansion to additional ophthalmic indications.

Future direct product sales of PRF-110 and OcuRing™-K post-approval.

This stream is entirely dependent on successful clinical progression and regulatory clearance. The current focus is on advancing the pipeline, not on current sales figures for these products.

Equity financing and capital raises to fund operations.

Since product sales are currently zero, operations are funded by capital raises and managing existing cash reserves. Here's a quick look at the funding and cash position as of mid-to-late 2025, based on the latest available figures.

Financial Metric	Amount (Millions USD)	Period End Date	Source
Cash and Cash Equivalents	$3.5	June 30, 2025
Positive Working Capital	$1.5	June 30, 2025
Net Loss (Six Months)	$2.3	June 30, 2025
Net Loss (Full Year)	$14.6	December 31, 2024
Public Offering Proceeds (Recent)	$0.9	2025 (via ATM program)
Public Offering Proceeds (Prior)	$4.0	April 2024

The company is definitely burning cash while advancing its pipeline, as shown by the net loss figures. Finance: draft 13-week cash view by Friday.